Levosulpride (Levosulpiride)

Overview

Levosulpride is the levorotatory (S) enantiomer of sulpiride, a substituted benzamide compound. It is the biologically active form of sulpiride and exhibits greater dopaminergic activity, better antiemetic/antidyspeptic effects, and lower acute toxicity than either the racemic mixture or the dextro (R) enantiomer.

Chemical Classification

Class: Substituted benzamide
Also known as: L-sulpiride, S-sulpiride, RV 12309
Brand names: Levopride, Levopraid, Dislep 25
Available as: 25 mg tablets, oral drops, parenteral ampoules

Mechanism of Action

Levosulpride is an atypical neuroleptic/prokinetic that acts by:

Selective D2 receptor blockade - preferentially blocks presynaptic dopaminergic D2 autoreceptors in brain dopaminergic pathways and in the gut
At low (prokinetic) doses: blocks D2 receptors in the gastrointestinal tract, which increases acetylcholine release, enhancing gut motility and accelerating gastric emptying
At higher (antipsychotic) doses: blocks central D2 receptors, producing antipsychotic and antidepressant effects by preferentially blocking presynaptic autoreceptors (which normally suppress dopamine release), thus paradoxically increasing synaptic dopamine in relevant pathways at low doses

Pharmacokinetics

Parameter	Value
Oral dose (antipsychotic)	400-1800 mg/day
Oral dose (antidepressant)	50-300 mg/day
Prokinetic dose	25-75 mg TDS
Plasma half-life (t½)	6-8 hours
Elimination	Primarily renal (unchanged)
Metabolism	Minimal hepatic metabolism

Indications

Psychiatric

Schizophrenia - effective against both positive and negative symptoms
Depression - particularly dysthymia and somatoform disorders
Anxiety disorders
Tourette's syndrome
Somatoform disorders

Gastrointestinal

Functional dyspepsia
Gastroesophageal reflux disease (GERD)
Irritable bowel syndrome (IBS)
Nausea and vomiting (antiemetic use)
Gastroparesis (including diabetic gastroparesis)
Peptic ulcer (adjunctive)

Other

Vertigo
Essential cephalgia (headache)
Premature ejaculation - a 2022 meta-analysis (PMID 36154321) confirmed its efficacy: 76.47% of treated patients showed improved ejaculatory control vs 26.66% on placebo
Diabetic macular oedema - under investigation in a 2024 Phase 2 RCT (PMID 37673971)

Advantages Over Racemic Sulpiride

Greater dopaminergic (D2) blocking potency
Stronger antiemetic and antidyspeptic efficacy
Lower acute toxicity
Better tolerability profile overall

Adverse Effects

Effect	Mechanism
Hyperprolactinaemia	D2 blockade in tuberoinfundibular pathway → gynecomastia, galactorrhoea, amenorrhoea
Extrapyramidal effects	Acute dystonia, tremor, akathisia
Sedation/drowsiness	Decreased sensory input to reticular activating system
Neuroleptic Malignant Syndrome (NMS)	Rare but serious - hyperpyrexia, rigidity, elevated CK
Tardive dyskinesia	With prolonged use
QT prolongation	Cardiac risk, especially with other QT-prolonging drugs

Drug Interactions

CNS depressants (benzodiazepines, opioids, alcohol): potentiated sedation
Other D2 blockers / antipsychotics: additive extrapyramidal and prolactin-raising effects
Drugs that prolong QT interval: increased risk of torsades de pointes

Contraindications

Prolactin-dependent tumours (e.g., breast cancer, pituitary prolactinoma)
Phaeochromocytoma
Severe renal impairment (requires dose reduction - primarily renal excretion)
Parkinson's disease (worsens dopamine deficiency)
History of NMS

Comparison to Related Drugs

Drug	Class	Key Distinction
Sulpiride (racemic)	Benzamide	Parent compound; less potent than levosulpride
Metoclopramide	Benzamide	Also D2 blocker; crosses BBB more readily, higher CNS side effects
Domperidone	Benzimidazole	D2 blocker; does NOT cross BBB significantly; less CNS effects
Amisulpride	Benzamide	Structural analogue; t½ ~12h; 48% bioavailability; also used psychiatrically
Itopride	Benzamide	D2 + AChE inhibitor; mainly GI prokinetic

Clinical Note

Levosulpride occupies a unique dual niche - at low doses it is a GI prokinetic (used by gastroenterologists), and at higher doses it is a psychiatric agent. This dose-dependent duality makes it important to titrate carefully and monitor for prolactin-related effects and extrapyramidal symptoms even at prokinetic doses, especially with long-term use.

This is a shared conversation. Sign in to Orris to start your own chat.